Developed Markets — Cost of Sales
Viatris Developed Markets — Cost of Sales remained flat by 0.0% to $1.02B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 1.9%, from $1.00B to $1.02B. Over 3 years (FY 2022 to FY 2025), Developed Markets — Cost of Sales shows relatively stable performance with a 0.5% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
A decrease relative to revenue indicates improved manufacturing efficiency or favorable product mix, while an increase may signal rising input costs.
Detailed definition
The direct costs attributable to the production and distribution of products sold within the Developed Markets segment,...
Peer comparison
Standard 'Cost of Goods Sold' (COGS) metric reported across all manufacturing and pharmaceutical segments.
vtrs_segment_developed_markets_cost_of_salesHistorical Data
| FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|
| Value | $4.03B | $4.07B | $4.01B | $4.09B |
| YoY Change | — | +1.0% | -1.3% | +1.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's developed markets — cost of sales?
- Viatris (VTRS) reported developed markets — cost of sales of $1.02B in Q4 2025.
- How has Viatris's developed markets — cost of sales changed year-over-year?
- Viatris's developed markets — cost of sales increased by 1.9% year-over-year, from $1.00B to $1.02B.
- What is the long-term trend for Viatris's developed markets — cost of sales?
- Over 3 years (2022 to 2025), Viatris's developed markets — cost of sales has grown at a 0.5% compound annual growth rate (CAGR), from $4.03B to $4.09B.
- What does developed markets — cost of sales mean?
- The direct costs incurred to produce and deliver goods sold in the Developed Markets segment.